Home › Linfoma diffuso a grandi cellule B › Massachusetts › Boston
Studi clinici su Linfoma diffuso a grandi cellule B a Boston, MA
16 studi su Linfoma diffuso a grandi cellule B cercano partecipanti presso sedi a Boston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
In reclutamentoFase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
In reclutamentoFase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
In reclutamentoFase 3
- Beth Israel Deaconess Medical Center, Boston
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
In reclutamentoFase 2
- Beth Israel Deaconess Medical Center ( Site 0161), Boston
- Dana Farber Cancer Institute ( Site 0111), Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
In reclutamentoFase 1/2
- Dana-Farber Cancer Institute ( Site 1013), Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
In reclutamentoFase 2
- Boston Medical Center, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
In reclutamentoFase 1/2
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
In reclutamentoStudio osservazionale
- Dana Farber Cancer Institute, Boston
The CARDIOPROTECT Trial
In reclutamentoFase 2
- Beth Israel Deaconess Medical Center, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
In reclutamentoFase 2
- Dana Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
In reclutamentoFase 1
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
In reclutamentoFase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
In reclutamentoFase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Studi su Linfoma diffuso a grandi cellule B in altre città
- New York City, NY21 studi
- Baldwin Park, CA19 studi
- Chicago, IL18 studi
- Houston, TX17 studi
- Los Angeles, CA17 studi
- Milwaukee, WI16 studi
- Portland, OR15 studi
- Nashville, TN15 studi
- Philadelphia, PA15 studi
- Durham, NC14 studi
- Dallas, TX13 studi
- Seattle, WA12 studi
Altri studi a Boston
- Cancro al seno111 studi
- Cancro del polmone non a piccole cellule90 studi
- Cancro (tutti i tipi)86 studi
- Cancro colorettale63 studi
- Cancro metastatico63 studi
- Cancro ai polmoni62 studi
- Cancro ovarico61 studi
- Cancro alla prostata59 studi
- Depressione52 studi
- Cancro dell'endometrio50 studi
- Insufficienza cardiaca44 studi
- Leucemia mieloide acuta44 studi
Fonte: ClinicalTrials.gov, dati recuperati il 3 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.